CRL Valuation

Charles River Laboratories International Inc

Add to Watchlist

Advanced Chart

163.360

+13.57(9.059%)1D

Overview
Forecast
Valuation
Earnings

CRL Relative Valuation

CRL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRL is overvalued; if below, it's undervalued.

Historical Valuation

Charles River Laboratories International Inc (CRL) is now in the Undervalued zone, suggesting that its current forward PE ratio of 16.57 is considered Undervalued compared with the five-year average of 23.30. The fair price of Charles River Laboratories International Inc (CRL) is between 182.68 to 285.37 according to relative valuation methord. Compared to the current price of 163.36 USD , Charles River Laboratories International Inc is Undervalued By 10.58%.

Relative Value

Fair Zone

182.68-285.37

Current Price：163.36

10.58%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.50

P/B

Median3y

3.17

Median5y

4.62

7.66

FCF Yield

Median3y

4.08

Median5y

3.67

Competitors Valuation Multiple

The average P/S ratio for CRL's competitors is 2.19, providing a benchmark for relative valuation. Charles River Laboratories International Inc Corp (CRL) exhibits a P/S ratio of 1.88, which is -14.20% above the industry average. Given its robust revenue growth of -2.71%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CRL.N

Charles River Laboratories International Inc

1.88

Average P/S: 2.19

-2.71%